Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Champions OncologyPluristem TherapeuticsX4 PharmaceuticalsERYTECH PharmaProtalix BioTherapeutics
SymbolNASDAQ:CSBRNASDAQ:PSTINASDAQ:XFORNASDAQ:ERYPNYSEAMERICAN:PLX
Price Information
Current Price$11.06$4.34$9.01$6.91$6.20
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score1.81.41.80.51.3
Analysis Score3.53.43.50.03.5
Community Score2.22.92.82.12.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.0
Earnings & Valuation Score1.90.61.30.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$16.00$9.75$18.60N/A$11.00
% Upside from Price Target44.67% upside124.65% upside106.44% upsideN/A77.42% upside
Trade Information
Market Cap$148.09 million$137.75 million$156.63 million$146.40 million$281.38 million
Beta1.22.530.532.732.87
Average Volume31,770707,508110,53223,738841,765
Sales & Book Value
Annual Revenue$32.12 million$20,000.00N/AN/A$54.69 million
Price / Sales4.616,887.58N/AN/A5.14
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.45 per share$2.20 per share$10.37 per share$5.34 per share($4.74) per share
Price / Book24.581.97N/AN/A-1.31
Profitability
Net Income$-1,980,000.00$-29,150,000.00$-52,810,000.00$-70,180,000.00$-18,280,000.00
EPS($0.17)N/A($4.63)($3.92)($1.23)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E Ratio73.73N/AN/AN/A620.00
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4.18%N/AN/AN/A-10.84%
Return on Equity (ROE)-29.93%-86.51%-47.06%N/AN/A
Return on Assets (ROA)-7.41%-68.23%-35.89%N/A-9.74%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.24%0.09%N/A
Current Ratio1.18%5.12%10.19%2.39%1.37%
Quick Ratio1.18%5.12%10.19%2.37%1.07%
Ownership Information
Institutional Ownership Percentage52.84%11.95%67.76%6.47%14.28%
Insider Ownership Percentage46.80%4.90%4.90%N/A1.64%
Miscellaneous
Employees14314672206196
Shares Outstanding13.39 million31.74 million17.38 million21.19 million45.38 million
Next Earnings Date7/26/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)N/A6/7/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Protalix Biotherapeutics Inc (PLX)Protalix Biotherapeutics Inc (PLX)
investing.com - April 16 at 10:24 PM
Here is a bargain stock you should look at : Protalix BioTherapeutics, Inc. (PLX)Here is a bargain stock you should look at : Protalix BioTherapeutics, Inc. (PLX)
marketingsentinel.com - April 12 at 5:28 PM
PLX: Target Action Date Four Weeks AwayPLX: Target Action Date Four Weeks Away
finance.yahoo.com - April 7 at 12:30 PM
Protalix BioTherapeutics Sees Unusually High Options Volume (NYSEAMERICAN:PLX)Protalix BioTherapeutics Sees Unusually High Options Volume (NYSEAMERICAN:PLX)
americanbankingnews.com - April 5 at 6:20 PM
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Announces Quarterly  Earnings ResultsProtalix BioTherapeutics (NYSEAMERICAN:PLX) Announces Quarterly Earnings Results
americanbankingnews.com - March 31 at 8:24 AM
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business ResultsProtalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
finance.yahoo.com - March 30 at 7:24 AM
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
finance.yahoo.com - March 22 at 7:21 AM
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceProtalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 8:02 AM
PLX: A Busy MonthPLX: A Busy Month
finance.yahoo.com - February 24 at 1:28 PM
Protalixs PRX–102 Monthly Treatment Shows Benefit In Fabry DiseaseProtalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease
finance.yahoo.com - February 23 at 12:14 PM
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry DiseaseProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
finance.yahoo.com - February 23 at 7:14 AM
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The CornerProtalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner
finance.yahoo.com - February 22 at 9:43 AM
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross ProceedsProtalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
finance.yahoo.com - February 18 at 8:14 AM
Protalix BioTherapeutics Raises $35M Via Equity At 21% DiscountProtalix BioTherapeutics Raises $35M Via Equity At 21% Discount
finance.yahoo.com - February 12 at 12:00 PM
US FDA grants rare pediatric disease & orphan drug designations to Polaryx Therapeutics’ PLX-300 to treat Krabbe diseaseUS FDA grants rare pediatric disease & orphan drug designations to Polaryx Therapeutics’ PLX-300 to treat Krabbe disease
pharmabiz.com - February 12 at 1:48 AM
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common StockProtalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
finance.yahoo.com - February 11 at 10:16 PM
Protalix BioTherapeutics Announces Proposed Public Offering of Common StockProtalix BioTherapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 11 at 5:16 PM
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory ConditionsProtalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions
finance.yahoo.com - February 11 at 10:53 AM
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled DeliveryProtalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
finance.yahoo.com - February 11 at 7:12 AM
Polaryx Therapeutics Receives Both Rare Pediatric…Polaryx Therapeutics Receives Both Rare Pediatric…
pharmiweb.com - February 11 at 5:45 AM
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
finance.yahoo.com - February 10 at 7:33 AM
Protalix BioTherapeutics, Inc. (NYSE:PLX) Shares Look Bullish in 2021Protalix BioTherapeutics, Inc. (NYSE:PLX) Shares Look Bullish in 2021
stocksregister.com - February 7 at 7:28 PM
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium(TM) 2021Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium(TM) 2021
stockhouse.com - February 2 at 6:22 PM
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021
finance.yahoo.com - February 1 at 7:24 AM
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in JanuaryProtalix BioTherapeutics to Participate in Upcoming Investor Conferences in January
markets.businessinsider.com - January 4 at 6:58 AM
DateCompanyBrokerageAction
3/22/2021Champions OncologyRoth CapitalBoost Price Target
11/27/2019Champions OncologyBenchmarkInitiated Coverage
7/24/2019Champions OncologyJanney Montgomery ScottDowngrade
2/27/2019Champions OncologyNational SecuritiesInitiated Coverage
7/17/2018Champions OncologyCraig HallumInitiated Coverage
5/15/2018Champions OncologyDawson JamesInitiated Coverage
12/10/2020Pluristem TherapeuticsJefferies Financial GroupDowngrade
12/7/2020Pluristem TherapeuticsHC WainwrightReiterated Rating
5/15/2020Pluristem TherapeuticsMaxim GroupReiterated Rating
7/22/2019Pluristem TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
3/22/2021X4 PharmaceuticalsOppenheimerReiterated Rating
12/17/2020X4 PharmaceuticalsBrookline Capital ManagementInitiated Coverage
11/30/2020X4 PharmaceuticalsB. RileyReiterated Rating
11/9/2020X4 PharmaceuticalsCanaccord GenuityLower Price Target
3/26/2020X4 PharmaceuticalsCitigroupLower Price Target
3/12/2020X4 PharmaceuticalsCowenReiterated Rating
6/7/2019X4 PharmaceuticalsStifel NicolausInitiated Coverage
9/5/2019ERYTECH PharmaJMP SecuritiesReiterated Rating
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.